A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma

Paola Orecchia, Romana Conte, Enrica Balza, Andrea Petretto, Pierluigi Mauri, Maria Cristina Mingari, Barbara Carnemolla

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Introduction: Syndecan-1 is a cell membrane protein that, after its shedding by heparanase enzymes, is accumulated in the extracellular matrix of some tumours, e.g. myeloma and lung carcinoma, where it modulates several key processes of tumourigenesis such as cancer cell proliferation and apoptosis, angiogenesis and metastasis. Few studies have focused on syndecan-1 in malignant melanoma, a tumour for which new therapeutic targets are desperately needed. We aimed to investigate the role of syndecan-1 in melanoma and to evaluate the potential therapeutic efficacy of a novel fully human anti-syndecan-1 recombinant antibody in this deadly disease. Methods: The OC-46F2 recombinant antibody was generated by selecting a human antibody phage display library on human melanoma cells and by its expression in mammalian cells. The specific antigen recognised by the antibody was identified by mass spectrometry. Murine models of human melanoma and ovarian carcinoma were used in the pre-clinical in vivo experiments. Results: The fully human antibody OC-46F2, specific for the extracellular domain of syndecan-1, inhibited vascular maturation and tumour growth in an experimental human melanoma model. The therapeutic efficacy of this antibody was also demonstrated in an experimental ovarian carcinoma model. A co-distribution of syndecan-1 with vascular endothelial growth factor receptor 2 (VEGFR2) observed in the intratumour melanoma microenvironment was absent in the tumours from mice treated with OC-46F2 scFv. Conclusion: These findings highlight the role of syndecan-1 as a potential therapeutic target in melanoma and ovarian carcinoma and provide a new tool able to block vessel maturation, one of the mechanisms that underpin the angiogenic process essential for solid tumour growth.

Original languageEnglish
Pages (from-to)2022-2033
Number of pages12
JournalEuropean Journal of Cancer
Volume49
Issue number8
DOIs
Publication statusPublished - May 2013

Fingerprint

Syndecan-1
Blood Vessels
Melanoma
Antibodies
Growth
Neoplasms
Carcinoma
Vascular Endothelial Growth Factor Receptor-2
Experimental Melanomas
Therapeutics
Bacteriophages
Libraries
Extracellular Matrix
Mass Spectrometry
Membrane Proteins
Cell Proliferation
Apoptosis
Neoplasm Metastasis
Antigens
Lung

Keywords

  • Angiogenesis
  • CD138
  • Human recombinant antibody
  • Melanoma
  • Ovarian carcinoma
  • Syndecan-1
  • Tumour growth
  • Vascular mimicry
  • VEGFR2

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma. / Orecchia, Paola; Conte, Romana; Balza, Enrica; Petretto, Andrea; Mauri, Pierluigi; Mingari, Maria Cristina; Carnemolla, Barbara.

In: European Journal of Cancer, Vol. 49, No. 8, 05.2013, p. 2022-2033.

Research output: Contribution to journalArticle

Orecchia, Paola ; Conte, Romana ; Balza, Enrica ; Petretto, Andrea ; Mauri, Pierluigi ; Mingari, Maria Cristina ; Carnemolla, Barbara. / A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma. In: European Journal of Cancer. 2013 ; Vol. 49, No. 8. pp. 2022-2033.
@article{545c26c373a24bb381b880342201e6a3,
title = "A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma",
abstract = "Introduction: Syndecan-1 is a cell membrane protein that, after its shedding by heparanase enzymes, is accumulated in the extracellular matrix of some tumours, e.g. myeloma and lung carcinoma, where it modulates several key processes of tumourigenesis such as cancer cell proliferation and apoptosis, angiogenesis and metastasis. Few studies have focused on syndecan-1 in malignant melanoma, a tumour for which new therapeutic targets are desperately needed. We aimed to investigate the role of syndecan-1 in melanoma and to evaluate the potential therapeutic efficacy of a novel fully human anti-syndecan-1 recombinant antibody in this deadly disease. Methods: The OC-46F2 recombinant antibody was generated by selecting a human antibody phage display library on human melanoma cells and by its expression in mammalian cells. The specific antigen recognised by the antibody was identified by mass spectrometry. Murine models of human melanoma and ovarian carcinoma were used in the pre-clinical in vivo experiments. Results: The fully human antibody OC-46F2, specific for the extracellular domain of syndecan-1, inhibited vascular maturation and tumour growth in an experimental human melanoma model. The therapeutic efficacy of this antibody was also demonstrated in an experimental ovarian carcinoma model. A co-distribution of syndecan-1 with vascular endothelial growth factor receptor 2 (VEGFR2) observed in the intratumour melanoma microenvironment was absent in the tumours from mice treated with OC-46F2 scFv. Conclusion: These findings highlight the role of syndecan-1 as a potential therapeutic target in melanoma and ovarian carcinoma and provide a new tool able to block vessel maturation, one of the mechanisms that underpin the angiogenic process essential for solid tumour growth.",
keywords = "Angiogenesis, CD138, Human recombinant antibody, Melanoma, Ovarian carcinoma, Syndecan-1, Tumour growth, Vascular mimicry, VEGFR2",
author = "Paola Orecchia and Romana Conte and Enrica Balza and Andrea Petretto and Pierluigi Mauri and Mingari, {Maria Cristina} and Barbara Carnemolla",
year = "2013",
month = "5",
doi = "10.1016/j.ejca.2012.12.019",
language = "English",
volume = "49",
pages = "2022--2033",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "8",

}

TY - JOUR

T1 - A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma

AU - Orecchia, Paola

AU - Conte, Romana

AU - Balza, Enrica

AU - Petretto, Andrea

AU - Mauri, Pierluigi

AU - Mingari, Maria Cristina

AU - Carnemolla, Barbara

PY - 2013/5

Y1 - 2013/5

N2 - Introduction: Syndecan-1 is a cell membrane protein that, after its shedding by heparanase enzymes, is accumulated in the extracellular matrix of some tumours, e.g. myeloma and lung carcinoma, where it modulates several key processes of tumourigenesis such as cancer cell proliferation and apoptosis, angiogenesis and metastasis. Few studies have focused on syndecan-1 in malignant melanoma, a tumour for which new therapeutic targets are desperately needed. We aimed to investigate the role of syndecan-1 in melanoma and to evaluate the potential therapeutic efficacy of a novel fully human anti-syndecan-1 recombinant antibody in this deadly disease. Methods: The OC-46F2 recombinant antibody was generated by selecting a human antibody phage display library on human melanoma cells and by its expression in mammalian cells. The specific antigen recognised by the antibody was identified by mass spectrometry. Murine models of human melanoma and ovarian carcinoma were used in the pre-clinical in vivo experiments. Results: The fully human antibody OC-46F2, specific for the extracellular domain of syndecan-1, inhibited vascular maturation and tumour growth in an experimental human melanoma model. The therapeutic efficacy of this antibody was also demonstrated in an experimental ovarian carcinoma model. A co-distribution of syndecan-1 with vascular endothelial growth factor receptor 2 (VEGFR2) observed in the intratumour melanoma microenvironment was absent in the tumours from mice treated with OC-46F2 scFv. Conclusion: These findings highlight the role of syndecan-1 as a potential therapeutic target in melanoma and ovarian carcinoma and provide a new tool able to block vessel maturation, one of the mechanisms that underpin the angiogenic process essential for solid tumour growth.

AB - Introduction: Syndecan-1 is a cell membrane protein that, after its shedding by heparanase enzymes, is accumulated in the extracellular matrix of some tumours, e.g. myeloma and lung carcinoma, where it modulates several key processes of tumourigenesis such as cancer cell proliferation and apoptosis, angiogenesis and metastasis. Few studies have focused on syndecan-1 in malignant melanoma, a tumour for which new therapeutic targets are desperately needed. We aimed to investigate the role of syndecan-1 in melanoma and to evaluate the potential therapeutic efficacy of a novel fully human anti-syndecan-1 recombinant antibody in this deadly disease. Methods: The OC-46F2 recombinant antibody was generated by selecting a human antibody phage display library on human melanoma cells and by its expression in mammalian cells. The specific antigen recognised by the antibody was identified by mass spectrometry. Murine models of human melanoma and ovarian carcinoma were used in the pre-clinical in vivo experiments. Results: The fully human antibody OC-46F2, specific for the extracellular domain of syndecan-1, inhibited vascular maturation and tumour growth in an experimental human melanoma model. The therapeutic efficacy of this antibody was also demonstrated in an experimental ovarian carcinoma model. A co-distribution of syndecan-1 with vascular endothelial growth factor receptor 2 (VEGFR2) observed in the intratumour melanoma microenvironment was absent in the tumours from mice treated with OC-46F2 scFv. Conclusion: These findings highlight the role of syndecan-1 as a potential therapeutic target in melanoma and ovarian carcinoma and provide a new tool able to block vessel maturation, one of the mechanisms that underpin the angiogenic process essential for solid tumour growth.

KW - Angiogenesis

KW - CD138

KW - Human recombinant antibody

KW - Melanoma

KW - Ovarian carcinoma

KW - Syndecan-1

KW - Tumour growth

KW - Vascular mimicry

KW - VEGFR2

UR - http://www.scopus.com/inward/record.url?scp=84876683956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876683956&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2012.12.019

DO - 10.1016/j.ejca.2012.12.019

M3 - Article

VL - 49

SP - 2022

EP - 2033

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 8

ER -